Key clinical point: Crizanlizumab was effective in sickle cell patients with numerous vaso-occlusive crises, the HbSS genotype, and those who use hydroxyurea.
Major finding: Crizanlizumab eliminated vaso-occlusive crises about seven times more frequently than did placebo in patients with numerous crises (28.0% vs. 4.2%).
Study details: A post hoc analysis of 132 patients from the phase 2 SUSTAIN trial.
Disclosures: The study was sponsored by Novartis. The authors reported financial relationships with Novartis, Bluebird Bio, AstraZeneca, and others.
Kutlar A et al. Am J Hematol. 2018 Oct 8. doi: 10.1002/ajh.25308.